Virtu Financial LLC grew its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 163.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,244 shares of the company’s stock after acquiring an additional 6,984 shares during the period. Virtu Financial LLC’s holdings in BioNTech were worth $1,070,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC increased its stake in shares of BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. EFG International AG acquired a new stake in shares of BioNTech during the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after buying an additional 260 shares in the last quarter. Huntington National Bank boosted its position in shares of BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have issued reports on the stock. Canaccord Genuity Group cut their price objective on shares of BioNTech from $171.00 to $158.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research report on Tuesday, March 17th. The Goldman Sachs Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $129.56.
Insider Activity
In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company’s stock.
BioNTech Stock Performance
NASDAQ:BNTX opened at $90.89 on Monday. The stock’s 50-day simple moving average is $94.55 and its 200 day simple moving average is $98.13. The firm has a market capitalization of $22.98 billion, a PE ratio of -15.46 and a beta of 1.33. The company has a quick ratio of 8.74, a current ratio of 8.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00.
BioNTech (NASDAQ:BNTX – Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. On average, analysts anticipate that BioNTech SE Sponsored ADR will post -5.67 EPS for the current fiscal year.
BioNTech announced that its board has authorized a share repurchase program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 4.2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.
BioNTech Profile
BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.
BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.
Featured Stories
- Five stocks we like better than BioNTech
- 3 Inflation-Fighting Stocks Built for Higher Oil Prices
- 3 Biotech Firms With Major Potential Catalysts in the Coming Months
- Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally?
- 3 Small-Cap Stocks Getting a Russell 2000 Rebalance Boost
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
